Allergan Aesthetics Posts 42-Point Satisfaction Gain in GLP-1 Users
Irvine, Calif. – November 08, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), reported a statistically significant 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance among 30 adults on GLP-1 medications who received combined neurotoxin and hyaluronic acid (HA) filler treatment. The result comes from HARMONY IN DIVERSITY, which the company describes as the first study of this combination in the GLP-1 population. Data from it and a second Phase 4 study, HALO, were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in San Diego, Nov. 5-8.